

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	4DS Memory Limited
ABN	43 145 590 110

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr David McAuliffe
Date of last notice	7 May 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Concept Biotech Pty Ltd (director related entity) David Jerimiah McAuliffe <The Lazy D9M Investment Trust> (trustee and beneficiary) Margaret Elizabeth Livingston (spouse)
Date of change	29 November 2019
No. of securities held prior to change	Direct <u>David McAuliffe</u> 2,521,839 fully paid ordinary shares Indirect <u>Concept Biotech Pty Ltd</u> 2,498,812 fully paid ordinary shares <u>David Jerimiah McAuliffe<D9M Investment Trust></u> 8,056,743 fully paid ordinary shares <u>Margaret Elizabeth Livingston</u> 7,000,000 unlisted options exercisable at \$0.052 each on or before 22 January 2024, with 1,250,000 subject to vesting conditions
Class	Fully paid ordinary shares
Number acquired	Direct – 245,901
Number disposed	-

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	Non-cash consideration. Issue of shares in lieu of accrued salary at a deemed issue price of \$0.061 per share as approved by shareholders at the annual general meeting held on 29 November 2019.
No. of securities held after change	Direct <u>David McAuliffe</u> 2,767,740 fully paid ordinary shares Indirect <u>Concept Biotech Pty Ltd</u> 2,498,812 fully paid ordinary shares <u>David Jeremiah McAuliffe<D9M Investment Trust></u> 8,056,743 fully paid ordinary shares <u>Margaret Elizabeth Livingston</u> 7,000,000 unlisted options exercisable at \$0.052 each on or before 22 January 2024, with 1,250,000 subject to vesting conditions
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares in lieu of accrued salary at a deemed issue price of \$0.061 per share as approved by shareholders at the annual general meeting held on 29 November 2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A-
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.